The GERAS Study - US was a prospective, multicenter, observational study that aimed to assess societal costs and resource use associated with AD among patients and their primary caregivers across 76 sites in the United States. Eligible patients were between the ages of 55 and 85 years at baseline, met criteria for early AD in the opinion of the enrolling physician, had Mini-Mental State Examination (MMSE) scores ≥20 and had study partners who were willing to participate. Participants were classified as mildly cognitively impaired ([MCI]; MMSE score 24-30 and Functional Activities Questionnaire [FAQ] <6) or MILD (mild dementia; MMSE 20-30 and FAQ ≥6). Subsequent stages further classified participants as either amyloid positive or negative. Data collected for patients and caregivers included demographics/clinical characteristics; current medication; patient cognitive, functional and behavioral assessments; patient and caregiver health-related quality of life (HRQoL); and patient and caregiver resource use. The costs associated with the resources used were calculated. Costs were broken down into patient healthcare costs, patient social care costs and caregiver informal care costs. A total of 1,198 patients were evaluated (300 MCI amyloid positive, 281 MCI amyloid negative, 317 MILD amyloid positive, 300 MILD amyloid negative). Overall, patients had a mean age of 70.4 years with a slight preponderance of females (55.3%).
To learn more about this clinical trial, visit the study record detail here.
To explore the data further, visit GAAIN: https://www.gaaindata.org/partner/GERAS
Manuscripts citing this dataset
- The Humanistic and Economic Burden of Alzheimer's Disease. 2022. DOI: https://doi.org/10.1007/s40120-022-00335-x
- Disease progression and costs at 3-year follow-up of GERAS-US: A 3-year study of mild cognitive impairment and mild dementia due to Alzheimer’s disease in the United States. 2021. DOI: https://doi.org/10.1002/alz.057473
Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer.
Data Use Agreement
More information on data access and use policies established by the trial sponsor can be found here.
Publishing results using this dataset?
The sponsor of this trial, Eli Lilly & Company, states their publication policy here.
Post a question or thought about this dataset here.